Incidence, diagnosis and pathophysiology of amniotic fluid embolism

Journal of Obstetrics and Gynaecology

Volumn 34, Issue 7, 2014, Pages 580-584

  Ito, F ^a   Akasaka, J ^a   Koike, N ^a   Uekuri, C ^a   Shigemitsu, A ^a   Kobayashi, H ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Amniotic fluid embolism; Anaphylaxis; Complement activation; Incidence; Pathophysiology

Indexed keywords

AMNION FLUID; AMNION FLUID ANALYSIS; AMNION FLUID EMBOLISM; ANAPHYLAXIS; ARTICLE; COMPLEMENT ACTIVATION; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FATALITY; HUMAN; IMMUNOCOMPETENT CELL; MATERNAL MORTALITY; PRIORITY JOURNAL; UNITED KINGDOM; CHEMISTRY; EMBOLISM, AMNIOTIC FLUID; FEMALE; IMMUNOLOGY; INCIDENCE; PREGNANCY;

BIOLOGICAL MARKER;

AMNIOTIC FLUID; BIOMARKERS; EMBOLISM, AMNIOTIC FLUID; FEMALE; HUMANS; INCIDENCE; PREGNANCY;

EID: 84925257020     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.3109/01443615.2014.919996     Document Type: Article

References (38)

1. Ahmed M, Abdullatif M. 2011. Fetomaternal transfusion as a cause of severe fetal anemia causing early neonatal death: a case report. Oman Medical Journal 26:444-446.
2. Attwood HD. 1956. Fatal pulmonary embolism by amniotic fluid. Journal of Clinical Pathology 9:38-46.
3. Benson MD. 1993. Nonfatal amniotic fluid embolism. Three possible cases and a new clinical definition. Archives of Family Medicine 2:989-994.
4. Benson MD. 2012. Current concepts of immunology and diagnosis in amniotic fluid embolism. Clinical and Developmental Immunology 2012:946576.
5. Benson MD, Cheema N, Kaufman MW, Goldschmidt RA, Beaumont JL. 2012. Uterine intravascular fetal material and coagulopathy at peripartum hysterectomy. Gynecologic and Obstetric Investigation 73:158-161.
6. Benson MD, Kobayashi H, Silver RK, Oi H, Greenberger PA, Terao T. 2001. Immunologic studies in presumed amniotic fluid embolism. Obstetrics and Gynecology 97:510-514.
7. Clark SL, Hankins GD, Dudley DA, Dildy GA, Porter TF. 1995. Amniotic fluid embolism: analysis of the national registry. American Journal of Obstetrics and Gynecology 172:1158-1167.
8. Clark SL, Pavlova Z, Greenspoon J, Horenstein J, Phelan JP. 1986. Squamous cells in the maternal pulmonary circulation. American Journal of Obstetrics and Gynecology 154:104-106.
9. Conde-Agudelo A, Romero R. 2009. Amniotic fluid embolism: an evidence-based review. American Journal of Obstetrics and Gynecology 201:445. e1-13.
10. del Balzo U, Polley MJ, Levi R. 1989. Cardiac anaphylaxis. Complement activation as an amplification system. Circulation Research 65:847-857.
11. Fineschi V, Gambassi R, Gherardi M, Turillazzi E. 1998. The diagnosis of amniotic fluid embolism: an immunohistochemical study for the quantification of pulmonary mast cell tryptase. International Journal of Legal Medicine 111:238-243.
12. Giampaolo C, Schneider V, Kowalski BH, Bellaver LA. 1987. The cytologic diagnosis of amniotic fluid embolism: A critical reappraisal. Diagnostic Cytopathology 3:126-128.
13. Gist RS, Staff ord IP, Leibowitz AB, Beilin Y. 2009. Amniotic fluid embolism. Anesthesia and Analgesia 108:1599-1602.
14. Gourley GR, Kreamer B, Arend R. 1990. Excremental studies in human neonates. Identification of zinc coproporphyrin as a marker for meconium. Gastroenterology 99:1705-1709.
15. Kanayama N, Inori J, Ishibashi-Ueda H, Takeuchi M, Nakayama M, Kimura S et al. 2011. Maternal death analysis from the Japanese autopsy registry for recent 16 years: significance of amniotic fluid embolism. Journal of Obstetrics and Gynaecology Research 37:58-63.
16. Kanayama N, Yamazaki T, Naruse H, Sumimoto K, Horiuchi K, Terao T. 1992. Determining zinc coproporphyrin in maternal plasma -a new method for diagnosing amniotic fluid embolism. Clinical Chemistry 38:526-529.
17. Knight M, Berg C, Brocklehurst P, Kramer M, Lewis G, Oats J et al. 2012. Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BioMed Central Pregnancy and Childbirth 12:7.
18. Knight M, Tuff nell D, Brocklehurst P, Spark P, Kurinczuk JJ. 2010. UK Obstetric Surveillance System. Incidence and risk factors for amniotic-fluid embolism. Obstetrics and Gynecology 115:910-917.
19. Kobayashi H. 2012. Th e entry of fetal and amniotic fluid components into the uterine vessel circulation leads to sterile inflammatory processes during parturition. Frontiers in Immunology 3:321.
20. Kobayashi H, Naruse K, Sado T, Noguchi T, Yoshida S, Shigetomi H et al. 2011. Search for amniotic fluid-specific markers: novel biomarker candidates for amniotic fluid embolism. Open Women's Health Journal 5:7-15.
21. Kobayashi H, Ohi H, Terao T. 1993. A simple, noninvasive, sensitive method for diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc. American Journal of Obstetrics and Gynecology 168:848-853.
22. Kobayashi T. 2010. [Amniotic fluid embolism-induced disseminated intravascular coagulation]. Acta Obstetrica et Gynaecologica Japonica 62:262-266.
23. Kramer MS, Rouleau J, Liu S, Bartholomew S, Joseph KS. 2012. Maternal Health Study Group of the Canadian Perinatal Surveillance System. Amniotic fluid embolism: incidence, risk factors, and impact on perinatal outcome. British Journal of Obstetrics and Gynaecology 119:874-879.
24. Kuhlman K, Hidvegi D, Tamura RK, Depp R. 1985. Is amniotic fluid material in the central circulation of peripartum patients pathologic? American Journal of Perinatology 2:295-299.
25. Leong AS, Norman JE, Smith R. 2008. Vascular and myometrial changes in the human uterus at term. Reproductive Sciences 15:59-65.
26. Moore J, Baldisseri MR. 2005. Amniotic fluid embolism. Critical Care Medicine 33:S279-S285.
27. Mulder JI. 1985. Amniotic fluid embolism: an overview and case report. American Journal of Obstetrics and Gynecology 152:430-435.
28. Naruse K, Noguchi T, Yoshida S, Tsunemi T, Shigetomi H, Oi H et al. 2012. Identification of interleukin-6 (IL-6) and squamous cell carcinoma (SCC) as amniotic fluid-specific markers. Open Journal of Obstetrics and Gynecology 2:147-150.
29. Nishio H, Matsui K, Miyazaki T, et al. 2002. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. Forensic Science International 126:53-56.
30. Oi H, Naruse K, Noguchi T, Sado T, Kimura S, Kanayama N et al. 2010. Fatal factors of clinical manifestations and laboratory testing in patients with amniotic fluid embolism. Gynecologic and Obstetric Investigation 70:138-144.
31. O'Shea A, Eappen S. 2007. Amniotic fluid embolism. International Anesthesiology Clinics 45:17-28.
32. Roberts CL, Algert CS, Knight M, Morris JM. 2010. Amniotic fluid embolism in an Australian population-based cohort. British Journal of Obstetrics and Gynaecology 117:1417-1421.
33. Rudra A, Chatterjee S, Sengupta S, Nandi B, Mitra J. 2009. Amniotic fluid embolism. Indian Society of Critical Care Medicine 13:129-135.
34. Stolk KH, Zwart JJ, Schutte J, VAN Roosmalen J. 2012. Severe maternal morbidity and mortality from amniotic fluid embolism in the Netherlands. Acta Obstetricia et Gynecologica Scandinavica 91:991-995.
35. Szebeni J, Baranyi L, Sávay S, Bodó M, Milosevits J, Alving CR et al. 2006. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. American Journal of Physiology. Heart and Circulatory Physiology 290:H1050-H1058.
36. Tsunemi T, Oi H, Sado T, Naruse K, Noguchi T, Kobayashi H. 2012. An overview of amniotic fluid embolism: past, present and future directions. Open Women's Health Journal 6:24-29.
37. Tuffnell DJ. 2005. United Kingdom amniotic fluid embolism register. British Journal of Obstetrics and Gynaecology 112:1625-1629.
38. Vercellotti GM, Hammerschmidt DE, Craddock PR, Jacob HS. 1982. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis. Blood 59: 1299-1304.